Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Icosapent ethyl for slowing progression of aortic valve stenosis
NL-OMON51414Phase 2Recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Jun 2023
- Modality
- Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in aortic stenosis (AS) and aortic valve calcification (CAVD) comparing Icosapent ethyl with Matching placebo (2 arms). Primary endpoint: Change in aortic valve calcium. Started Jun 2023; status: recruiting.
02
Drugs
omega-3-acid triglycerides
03
Conditions
aortic stenosis (AS)aortic valve calcification (CAVD)
Beyond the preview
Go deeper on NL-OMON51414.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51414.